Evidence map›Paper›PMID 30892557›Full record

ArticleJAMA cardiology2019

Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease: An Analysis of the US Renal Data System.

Zubin J Modi, Yee Lu, Nan Ji, Alissa Kapke, David T Selewski, Xue Dietrich, Kevin Abbott, Brahmajee K Nallamothu, Douglas E Schaubel, Rajiv Saran and 1 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in JAMA cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 4 pooled it
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 4 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Peritoneal dialysis versus haemodialysis for people commencing dialysis.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Bioelectrical Impedance in Pediatric Dialysis: Clinical Applications, Limitations, and Opportunities.Hemodialysis international. International Symposium on Home Hemodialysis · 2026
    Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. A guide to uraemic toxicity.Nature reviews. Nephrology · 2026
    Review
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Zubin J ModiDivision of Pediatric Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor.
Yee LuDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor.
Nan JiArbor Research Collaborative for Health, Ann Arbor, Michigan.
Alissa KapkeArbor Research Collaborative for Health, Ann Arbor, Michigan.
David T SelewskiDivision of Pediatric Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor.
Xue DietrichArbor Research Collaborative for Health, Ann Arbor, Michigan.
Kevin AbbottNational Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Kidney Urology and Epidemiology, Bethesda, Maryland.
Brahmajee K NallamothuDivision of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor.
Douglas E SchaubelDepartment of Biostatistics, School of Public Health, University of Michigan, Ann Arbor.
Rajiv SaranDivision of Nephrology, Department of Internal Medicine, University of Michigan, Ann Arbor.
Debbie S GipsonDivision of Pediatric Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor.
University of Michigan–Ann Arbor · USArbor Research Collaborative for Health · USAnn Arbor VA Medical Center · USNational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

RESEARCH TRAINING IN NEPHROLOGYT32DK007378 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PENNATHUR, SUBRAMANIAM · 1986 to 2019
$5.9M
Survival Analysis Methods for Organ Failure DataR01DK070869 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI DOUGLAS EARL SCHAUBEL · 2005 to 2026
$4.7M
NIDDK NIH HHS R01 DK070869NIDDK NIH HHS T32 DK007378
6 · The paper itself

Abstract

Importance: Cardiovascular disease (CVD) is a leading cause of death among patients with end-stage renal disease (ESRD). Young adult (ages 22-29 years) have risks for ESRD-associated CVD that may vary from other ages. Objective: To test the hypothesis that young adult-onset ESRD is associated with higher cardiovascular (CV) hospitalizations and mortality with different characteristics than childhood-onset disease. Design, Setting, and Participants: This population-based cohort study used the US Renal Data System to categorize patients who initiated ESRD care between 2003 and 2013 by age at ESRD onset (1-11, 12-21, and 22-29 years). Cardiovascular hospitalizations were identified via International Classification of Diseases, Ninth Revision discharge codes and CV mortality from the Centers for Medicare & Medicaid ESRD Death Notification Form. Patients were censored at death from non-CVD events, loss to follow-up, recovery, or survival to December 31, 2014. Adjusted proportional hazard models (95% CI) were fit to determine risk of CV hospitalization and mortality by age group. Data analysis occurred from May 2016 and December 2017. Exposures: Onset of ESRD. Main Outcomes and Measures: Cardiovascular mortality and hospitalization. Results: A total of 33 156 patients aged 1 to 29 years were included in the study population. Young adults (aged 22-29 years) had a 1-year CV hospitalization rate of 138 (95% CI, 121-159) per 1000 patient-years. Young adults had a higher risk for CV hospitalization than children (aged 1-11 years; hazard ratio [HR], 0.41 [95% CI, 0.26-0.64]) and adolescents (aged 12-21 years; HR, 0.86 [95% CI, 0.77-0.97]). Of 4038 deaths in young adults, 1577 (39.1%) were owing to CVD. Five-year cumulative incidence of mortality in this group (7.3%) was higher than in younger patients (adolescents, 4.0%; children, 1.7%). Adjusted HRs for CV mortality were higher for young adults with all causes of ESRD than children (cystic, hereditary, and congenital conditions: HR, 0.22 [95% CI, 0.11-0.46]; P < .001; glomerulonephritis: HR, 0.21 [95% CI, 0.10-0.44]; P < .001; other conditions: HR, 0.33 [95% CI, 0.23-0.49]; P < .001). Adolescents had a lower risk for CV mortality than young adults for all causes of ESRD except glomerulonephritis (cystic, hereditary, and congenital conditions: HR, 0.45 [95% CI, 0.27-0.74]; glomerulonephritis: HR, 0.99 [95% CI, 0.76-1.11]; other: HR, 0.47 [95% CI, 0.40-0.57]). Higher risks for CV hospitalization and mortality were associated with lack of preemptive transplant compared with hemodialysis (hospital: HR, 14.24 [95% CI, 5.92-34.28]; mortality: HR, 13.64 [95% CI, 8.79-21.14]) and peritoneal dialysis [hospital: HR, 8.47 [95% CI, 3.50-20.53]; mortality: HR, 7.86 [95% CI, 4.96-12.45]). Nephrology care before ESRD was associated with lower risk for CV mortality (HR, 0.77 [95% CI, 0.70-0.85]). Conclusions and Relevance: Cardiovascular disease accounted for nearly 40% of deaths in young adults with incident ESRD in this cohort. Identified risk factors may inform development of age-appropriate ESRD strategies to improve the CV health of this population.

Indexed as

AdolescentAdultCardiovascular DiseasesChildChild, PreschoolFemaleHospitalizationHumansIncidenceInfantKidney Failure, ChronicKidney TransplantationMaleMortalityOutcome Assessment, Health CareRenal Dialysis

Identifiers

PMID30892557
PMCPMC6484951
OpenAlexW2925263652

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.